i3 Health and Oncology Data Advisor Publish Multiple Myeloma Task Force Position Statement in Blood Cancer Journal
Expert Perspectives · Keira Smith · 2024-09-05
i3 Health and Oncology Data Advisor are pleased to announce the publication of our Multiple Myeloma Task Force position statement in Blood Cancer Journal.
The position statement, titled “Disparities in Relapsed or Refractory Multiple Myeloma: Recommendations From an Interprofessional Consensus Panel,” is authored by the six Task Force members:
- Sikander Ailawadhi, MD, Professor of Medicine in the Division of Hematology/Oncology and Lead of the International Cancer Center at the Mayo Clinic
- Rahul Banerjee, MD, FACP, Assistant Professor in the Division of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington
- Yelak Biru, MSc, President and CEO of the International Myeloma Foundation
- Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute
- Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, Nurse Practitioner at the Cleveland Clinic Taussig Cancer Institute
- Shonali Midha, MD, Medical Oncologist at Jerome Lipper Multiple Myeloma Center and Instructor at Harvard Medical School and Dana-Farber Cancer Institute
The Multiple Myeloma Task Force also held a live YouTube discussion (@i3Health on YouTube) in which they highlighted strategies for mitigating disease burden and healthcare disparities in relapsed/refractory multiple myeloma. In the position statement, they further delve into factors that can inform treatment selection for relapsed/refractory multiple myeloma, the clinical significance of measurable residual disease (MRD) negativity, current and emerging combination and sequential treatment strategies for patients experience early and late relapse, and interprofessional strategies for reducing disparities in multiple myeloma care.
“The vast majority of literature around disparities in multiple myeloma focuses on diagnosis and the frontline setting. With this position statement, we took a slightly different approach,” commented Dr. Banerjee. “We decided to focus on disparities in the relapsed/refractory setting, where very little is known despite a myriad of novel therapeutic options. Our hope for this position statement is that it will contribute to conscious efforts to ensure equally accessible care for all patients with relapsed/refractory multiple myeloma as the treatment landscape continues to expand.”
Read the Multiple Myeloma Task Force position statement as an open-access article in Blood Cancer Journal today, and stay tuned for the upcoming podcast episode in which Dr. Ailawadhi and Dr. Banerjee further explore these important themes.